Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: A meta-analysis

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 757-765

  Hoffmann, Philipp ^a,b   Keller, Frieder ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Bleeding; Enoxaparin; GFR; Kidney dysfunction; Major bleeding; Meta analysis

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARINOID; TINZAPARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING; CHRONIC KIDNEY DISEASE; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG USE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; ENOXAPARIN; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; RENAL INSUFFICIENCY; RENAL INSUFFICIENCY, CHRONIC; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84864286726     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1149-6     Document Type: Article

References (33)

1. Barras MA, Duffull SB, Atherton JJ, Green B (2009) Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol 68(5):700-711
2. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, Blais N, Lalonde L (2005) Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116(1):41-50 (Pubitemid 40546324)
3. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharma-cokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143(5):753-759 (Pubitemid 34595330)
4. Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderink GJ, Becker R, Antman EM (2003) Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 56(4):407-414 (Pubitemid 37188135)
5. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140(11):867-873
6. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A (2003) Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 43 (6):586-590 (Pubitemid 36613117)
7. Clark N (2008) Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res 123(1):58-61
8. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A (2001) Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 80(1):81-82 (Pubitemid 32800808)
9. Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, Ankri A, Dumaine R, Lesty C, Vignolles N, Thomas D (2003) Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 41 (1):8-14 (Pubitemid 36044396)
10. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, Lopez-Sendon J, Laufenberg CV, Klutman M, Gowda N, Gulba D (2005) Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 26 (21):2285-2293 (Pubitemid 41541393)
11. Despotovic N, Erceg P, Nikolic-Despotovic M, Milosevic DP, Davidovic M (2007) Bleeding during enoxaparin treatment more common with age over 75 years and severe renal insufficiency. Drugs Aging 24(9):777-779 (Pubitemid 47378291)
12. Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR (2006) Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Br J Clin Pharmacol 62(2):165-176 (Pubitemid 44316428)
13. Fillastre JP, Leroy A, Baudoin C, Humbert G, Swabb EA, Vertucci C, Godin M (1985) Pharmacokinetics of aztreonam in patients with chronic renal failure. Clin Pharmacokinet 10 (1):91-100 (Pubitemid 15198243)
14. Fox KA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FW, Lopez-Sendon J, Hod H, Murphy SA, Braunwald E (2007) The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49(23):2249-2255 (Pubitemid 46863477)
15. Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S (2007) Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 147(5):304-310 (Pubitemid 351664557)
16. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J (2005) Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 59(3):281-290 (Pubitemid 40388082)
17. Hammerstingl C, Omran H (2009) Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. Thromb Haemost 101(6):1085-1090
18. Hammerstingl C, Tripp C, Schmidt H, von der Recke G, Omran H (2007) Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 16 (3):285-292 (Pubitemid 46887057)
19. Hammerstingl C, Omran H, Tripp C, Poetzsch B (2009) How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. Thromb Haemost 101 (2):325-332
20. Khazan M, Scheuering S, Adamson R, Mathis AS (2003) Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. Pharmacotherapy 23(5):651-658 (Pubitemid 36546193)
21. Kruse MW, Lee JJ (2004) Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 148(4):582-589 (Pubitemid 39349375)
22. Lim W (2008) Low-molecular-weight heparin in patients with chronic renal insufficiency. Intern Emerg Med 3(4):319-323
23. Macie C, Forbes L, Foster GA, Douketis JD (2004) Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 125(5):1616-1621 (Pubitemid 38648388)
24. Mahe I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K, Heilmann JJ, Mottier D, Bergmann JF (2007) Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97 (4):581-586 (Pubitemid 46592936)
25. Mahe I, Gouin-Thibault I, Drouet L, Simoneau G, Di Castillo H, Siguret V, Bergmann JF, Pautas E (2007) Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging 24(1):63-71 (Pubitemid 46148082)
26. McKeage K, Lyseng-Williamson KA (2010) Fondaparinux: a pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome. Pharmacoeconomics 28(8):687-698
27. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D (2004) Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110(4):392-398 (Pubitemid 38993847)
28. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43 (6):1064-1083
29. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX (2002) Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 105(3):225-231 (Pubitemid 34260945)
30. Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 139(31-32):438-452
31. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM (2003) Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146(1):33-41 (Pubitemid 36851297)
32. Spinler SA, Mahaffey KW, Gallup D, Levine GN, Ferguson JJ, 3 rd, Rao S V, Gallo R, Ducas J, Goodman SG, Antman E, White HD, Biasucci L, Becker RC, Col JJ, Cohen M, Harrington RA, and Califf RM (2009) Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results: from SYNERGY. Int J Cardiol [Epub ahead of print]
33. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA (2004) Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 125 (3):856-863 (Pubitemid 38367274)